In 2018, colorectal cancer (CRC) is estimated to affect 140,250 individuals in the United States and over one-half of these patients will develop liver metastases. Although surgical resection remains one of the major curative treatment options available to patients with colorectal liver metastases, it continues to be a controversial and evolving topic. As medical management and surgical techniques continue to advance in safety and efficacy, patients initially deemed unresectable can now be identified and have the potential to become resectable through preoperative treatment measures. In addition, given the extensive molecular and clinical heterogeneity of CRC, it is essential to individualize therapy on the basis of molecular profiling to avoid treatment-related toxicities without a recognized survival benefit.
Both primary liver cancer (HCC) and cholangiocarcinoma (CC) pose numerous clinical challenges. Over the last two years, the treatment landscape and biologic understanding of primary liver tumors has shifted dramatically with significant advancements in, loco-regional and systemic therapies rapidly being developed. Several large randomized phase III trials of novel treatments have resulted in new drug approvals and the increased knowledge of specific pathways implicated in tumor growth has shifted the focus of many clinical trials and treatments.
In light of these exciting new developments, this conference has been customized to provide the latest evidence based practice to health care professionals. Each session will address how expanding treatment choices and research studies will influence individual treatment plans and impact patient management in the future. Don’t miss out on this important and informative symposium. MORE